Efficacy of Vandetanib

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved vandetanib, trade name CAPRELSA, for adults with metastatic medullary thyroid carcinoma (MTC). Vandetanib appears to be effective in adolescents and children with metastatic or locally advanced medullary thyroid carcinoma. Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are ineffective, and some tyrosine kinase inhibitors (TKIs) have been tested in clinical trials in patients with pMTC.

Vandetanib has been shown to improve progression-free survival (30.5 months in the control group versus 19.3 months in the control group) in patients with advanced or metastatic progressive medullary thyroid cancer (pMTC). The most common adverse events in patients receiving vandetanib were diarrhea, rash, folliculitis, nausea, QTc prolongation, hypertension, and fatigue. Vandetanib has shown promising results in patients with aggressive differentiated thyroid cancer. According to pharmacokinetic studies, vandetanib is well absorbed in the intestine and reaches peak plasma concentration 4-10 hours after administration. The average half-life is 19 days. Patients must take vandetanib for about three months to reach steady-state concentration.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.